

GLAXOSMITHKLINE PLC
Form 6-K
January 16, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 16 January 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley
 Chief Executive Officer
 b) Position/status

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s)	Volume(s)
£13.306	87.861

£13.306	87.861
---------	--------

£13.306	217.580
---------	---------

c) Price(s) and volume(s)

£13.306	217.564
---------	---------

£13.306	236.894
---------	---------

£13.306	236.879
---------	---------

Aggregated information

d) Aggregated volume Price 1,084.639
 £13.306

e) Date of the transaction 2018-01-11

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr R G Connor
- b) Position/status President, Global Manufacturing & Supply
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
- | Price(s) | Volume(s) |
|----------|-----------|
| £13.306 | 64.344 |
| £13.306 | 64.344 |
- c) Price(s) and volume(s)
- | | |
|---------|---------|
| £13.306 | 147.828 |
| £13.306 | 123.348 |
| £13.306 | 123.334 |
- d) Aggregated information
- | | |
|-------------------|---------|
| Aggregated volume | 523.198 |
| Price | £13.306 |
- e) Date of the transaction 2018-01-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr L Debruyne
b) Position/status President, Global Vaccines
c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
- | Price(s) | Volume(s) |
|----------|-----------|
| £13.306 | 207.321 |
| £13.306 | 207.306 |
- c) Price(s) and volume(s)
- d) Aggregated information
- | Aggregated volume | Price |
|-------------------|---------|
| 414.627 | £13.306 |
- e) Date of the transaction 2018-01-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
b) Position/status Chief Financial Officer
c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each

place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £13.306 122.724
	£13.306 122.707
	£13.306 287.332
	£13.306 287.316
	£13.306 215.211
d) Aggregated information	
Aggregated volume	1,250.501
Price	£13.306
e) Date of the transaction	2018-01-11
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr N Hiron
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£13.306 45.052
	£13.306 45.052
c) Price(s) and volume(s)	£13.306 106.239
	£13.306 106.239
	£13.306 77.966
	£13.306 77.951
d) Aggregated information	
Aggregated volume	458.499
Price	£13.306
e) Date of the transaction	2018-01-11
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr B McNamara
b) Position/status	CEO, GSK Consumer Healthcare
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
a) Description of the financial instrument	

American Depositary Shares
('ADSs')
ISIN: US37733W1053

b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 January 2018 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
\$36.84 87.876

Aggregated information
d) Aggregated volume Price

87.876
\$36.84

e) Date of the transaction 2018-01-11
f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
Price(s) Volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£13.306 72.194

£13.306 72.194

£13.306 135.207

£13.306 135.207

£13.306 98.121

£13.306 98.106

Aggregated information

d) Aggregated volume Price

611.029
£13.306

e) Date of the transaction

2018-01-11

f) Place of the transaction

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s) Volume(s)
£13.306 97.174

£13.306 97.158

c) Price(s) and volume(s)

£13.306	197.805
£13.306	197.805
£13.306	147.686
£13.306	147.686

Aggregated information

d) Aggregated volume Price
 885.314
 £13.306

e) Date of the transaction 2018-01-11
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
 b) Position/status President, Global Affairs
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument
 Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

Price(s)	Volume(s)
£13.306	66.002

c) Price(s) and volume(s) £13.306 121.024

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

£13.306 92.975

- Aggregated information
- d) Aggregated volume Price 280.001
£13.306
- e) Date of the transaction 2018-01-11
- f) Place of the transaction London Stock Exchange
(XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D E Troy
- b) Position/status SVP & General Counsel
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares
(‘ADSs’)
ISIN: US37733W1053
- b) Nature of the transaction Acquisition of ADSs
following the re-investment
of dividends paid to
shareholders on 11 January
2018 on ADSs held in the
Company's 2009 Deferred
Annual Bonus Plan.
- | Price(s) | Volume(s) |
|----------|-----------|
| \$36.84 | 50.006 |
| \$36.84 | 50.006 |
| \$36.84 | 112.593 |
| \$36.84 | 112.593 |
| \$36.84 | 93.253 |
| \$36.84 | 93.239 |
- c) Price(s) and volume(s)
- d) Aggregated information

Aggregated volume Price

511.690
\$36.84

- e) Date of the transaction 2018-01-11
f) Place of the transaction New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
b) Position/status President, R&D

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 January 2018 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.

	Price(s)	Volume(s)
	£13.306	143.039
	£13.306	143.039
c) Price(s) and volume(s)	£13.306	232.681
	£13.306	232.681
	£13.306	160.411
	£13.306	160.411

d) Aggregated information

Aggregated volume Price

1,072.262
£13.306

e) Date of the transaction 2018-01-11
f) Place of the transaction London Stock Exchange
(XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 16, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc